Heat-shock proteins (HSPs) are antigen-presenting protein-aggregation-preventing chaperones, induced by cellular stress in eukaryotic cells. In this review, we focus on recent HSP advances in neurological disorders. In myasthenia gravis, patients responding to immunosuppressive therapy have reduced serum HSP-71 antibodies. Generalized and ocular myasthenia gravis patients have elevated serum HSP-70 antibodies, indicating common pathogenic mechanisms. In Guillain-Barré syndrome, HSP-70 antibodies are elevated in serum and cerebrospinal fluid, and serum levels are higher than in myasthenia gravis and multiple sclerosis. In multiple sclerosis, serum HSP-27 antibodies are elevated during relapses providing disease activation marker, while α,β-crystallin expression in brain lesions indicates remission phase initiation. In acute stroke, serum HSP-27 antibodies are elevated irrespective of stroke type and duration. In epilepsy, HSP-27 is induced in patients’ astrocytes and cerebral blood vessel walls, and α,β-crystallin is expressed in epileptic foci. In neurodegenerative disorders such as Alzheimer dementia and Parkinson’s disease, HSPs are upregulated in brain tissue, and α,β-crystallin modulates superoxide dismutase-1 (SOD-1) tissue accumulation in familial amyotrophic lateral sclerosis. HSPs play an important role in antigen-presentation and tolerance development. Antibody-mediated interference with their function alters immune responses causing neuropathology. The role of HSPs in clinical neurology should be the subject of future investigation.

Keywords:
Heat-shock proteins, Myasthenia gravis, Guillain-Barré syndrome, Multiple sclerosis, Stroke, Epilepsy
1.
Multhoff G: Heat-shock protein 70 (Hsp70): membrane location, export and immunological relevance. Methods 2007;43:229–237.
2.
Bukau B, Horwich AL: The Hsp70 and Hsp60 chaperone machines. Cell 1998;92:351–366.
3.
Tsan MF, Gao B: Heat-shock protein and innate immunity. Cell Mol Immunol 2004;1:274–279.
4.
Li Z, Menoret A, Srivastava P: Roles of heat-shock proteins in antigen presentation and cross-presentation. Curr Opin Immunol 2002;14:45–51.
5.
Wang Y, Kelly CG, Singh M, McGowan EG, Carrara AS, Bergmeier LA, Lehner T: Stimulation of Th1-polarizing cytokines, C-C chemokines, maturation of dendritic cells, and adjuvant function by the peptide binding fragment of heat-shock protein 70. J Immunol 2002;169:2422–2429.
6.
Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW, Koo GC, Calderwood SK: HSP70 stimulates cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000;6:435–442.
7.
Tebo AE, Szankasi P, Hillman TA, Litwin CM, Hill HR: Antibody reactivity to heat-shock protein 70 and inner ear-specific proteins in patients with idiopathic sensorineural hearing loss. Clin Exp Immunol 2006;146:427–432.
8.
Tasneem S, Islam N, Ali R: Cross-reactivity of SLE autoantibodies with 70 kDa heat-shock proteins of Mycobacterium tuberculosis. Microbiol Immunol 2001;45:841–846.
9.
Zlacka D, Vavrincova P, Hien Nguyen TT, Hromadnikova I: Frequency of anti-Hsp-60, -65 and -70 antibodies in sera of patients with juvenile idiopathic arthritis. J Autoimmun 2006;27:81–88.
10.
Yusuf N, Nasti TH, Huang CM, Huber BS, Jaleel T, Lin HY, Xu H, Elmets CA: Heat-shock proteins HSP27 and HSP70 are present in the skin and are important mediators of allergic contact hypersensitivity. J Immunol 2009;182:675–683.
11.
Birtas-Atesoglu E, Inanc N, Yavuz S, Ergun T, Direskeneli H: Serum levels of free heat-shock protein 70 and anti-HSP70 are elevated in Behçet’s disease. Clin Exp Rheumatol 2008;26:S96–S98.
12.
Ratanachaiyavong S, Demaine AG, Campbell RD, McGregor AM: Heat-shock protein 70 (HSP70) and complement C4 genotypes in patients with hyperthyroid Graves’ disease. Clin Exp Immunol 1991;84:48–52.
13.
Hunt PJ, Marshall SE, Weetman AP, Bunce M, Bell JI, Wass JA, Welsh KI: Histocompatibility leucocyte antigens and closely linked immunomodulatory genes in autoimmune thyroid disease. Clin Endocrinol (Oxf) 2001;55:491–499.
14.
Zhang ZY, Zhang Z, Schluesener HJ: Toll-like receptor-2, CD14 and heat-shock protein 70 in inflammatory lesions of rat experimental autoimmune neuritis. Neuroscience 2009;159:136–142.
15.
Millar DG, Garza KM, Odermatt B, Elford AR, Ono N, Li Z, Ohashi PS: Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo. Nat Med 2003;9:1469–1476.
16.
Stetler RA, Gao Y, Signore AP, Cao G, Chen J: HSP27: mechanisms of cellular protection against neuronal injury. Curr Mol Med 2009;9:863–872.
17.
Lindstrøm JM, Seybold ME, Lennon VA, Whittingham S, Duane DD: Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. 1975 classical article. Neurology 1998;51:933–939.
18.
Luchanok U, Kaminski HJ: Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Curr Opin Neurol 2008;21:8–15.
19.
Evoli A, Batocchi AP, Minisci C, Di Schino C, Tonali P: Therapeutic options in ocular myasthenia gravis. Neuromuscul Disord 2001;11:208–216.
20.
Wilcox N: Myasthenia gravis. Curr Opin Immunol 1993;5:910–917.
21.
Li Z, Forester N, Vincent A: Modulation of acetylcholine receptor function in TE671 (rhabdomyosarcoma) cells by non-AchR ligands: possible relevance to seronegative myasthenia gravis. J Neuroimmunol 1996;64:179–183.
22.
Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A: Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365–368.
23.
McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, Vincent A: Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004;55:580–584.
24.
Fuhrer C, Sugiyama JE, Taylor RG, Hall ZW: Association of muscle-specific kinase MuSK with the acetylcholine receptor in mammalian muscle. EMBO J 1997;16:4951–4960.
25.
Borges LS, Ferns M: Agrin-induced phosphorylation of the acetylcholine receptor regulates cytoskeletal anchoring and clustering. J Cell Biol 2001;153:1–11.
26.
Romi F, Skeie GO, Gilhus NE, Aarli JA: Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol 2005;62:442–446.
27.
Munakata S, Chen M, Aosai F, Kawaguchi N, Nemoto Y, Norose K, Hattori T, Yano A: The clinical significance of anti-heat-shock cognate protein 71 antibody in myasthenia gravis. J Clin Neurosci 2008;15:158–165.
28.
Helgeland G, Petzold A, Hoff JM, Gilhus NE, Plant GT, Romi FR: Anti-heat-shock protein 70 antibody levels are increased in myasthenia gravis and Guillain-Barré syndrome. J Neuroimmunol 2010;225:180–183.
29.
Yonekura K, Yokota S, Tanaka S, Kubota H, Fujii N, Matsumoto H, Chiba S: Prevalence of anti-heat-shock protein antibodies in cerebrospinal fluids of patients with Guillain-Barré syndrome. J Neuroimmunol 2004;156:204–209.
30.
Salvetti M, Ristori G, Buttinelli C, Fiori P, Falcone M, Britton W, Adams E, Paone G, Grasso MG, Pozzilli C: The immune response to mycobacterial 70-kDa heat-shock proteins frequently involves autoreactive T cells and is quantitatively dysregulated in multiple sclerosis. J Neuroimmunol 1996;65:143–153.
31.
Ce P, Erkizan O, Gedizlioglu M: Elevated HSP27 levels during attacks in patients with multiple sclerosis. Acta Neurol Scand 2011 (Epub ahead of print).
32.
Stoevring B, Vang O, Christiansen M: α,β-crystallin in cerebrospinal fluid of patients with multiple sclerosis. Clin Chim Acta 2005;356:95–101.
33.
Van Noort JM, Verbeek R, Meilof JF, Polman CH, Amor S: Autoantibodies against α,β-crystallin, a candidate autoantigen in multiple sclerosis, are part of a normal human immune repertoire. Mult Scler 2006;12:287–293.
34.
Sinclair C, Mirakhur M, Kirk J, Farrell M, McQuaid S: Up-regulation of osteopontin and α,β-crystallin in the normal-appearing white matter of multiple sclerosis: an immunohistochemical study utilizing tissue microarrays. Neuropathol Appl Neurobiol 2005; 31:292–303.
35.
Steinman L: A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol 2009;9:440–447.
36.
Azarpazhooh MR, Mobarra N, Parizadeh SM, Tavallaie S, Bagheri M, Rahsepar AA, Ghayour-Mobarhan M, Sahebkar A, Ferns GA: Serum high-sensitivity C-reactive protein and heat-shock protein 27 antibody titers in patients with stroke and 6-month prognosis. Angiology 2010;61:607–612.
37.
Liebelt B, Papapetrou P, Ali A, Guo M, Ji X, Peng C, Rogers R, Curry A, Jimenez D, Ding Y: Exercise preconditioning reduces neuronal apoptosis in stroke by up-regulating heat-shock protein-70 (heat-shock protein-72) and extracellular-signal-regulated-kinase 1/2. Neuroscience 2010;166:1091–1100.
38.
Van der Weerd L, Tariq Akbar M, Aron Badin R, Valentim LM, Thomas DL, Wells DJ, Latchman DS, Gadian DG, Lythgoe MF, de Belleroche JS: Overexpression of heat-shock protein 27 reduces cortical damage after cerebral ischemia. J Cereb Blood Flow Metab 2010;30:849–856.
39.
Goldstein LB: Physical activity and the risk of stroke. Expert Rev Neurother 2010;10:1263–1265.
40.
Zhang F, Wu Y, Jia J: Exercise preconditioning and brain ischemic tolerance. Neuroscience 2011;177:170–176.
41.
Bidmon HJ, Görg B, Palomero-Gallagher N, Behne F, Lahl R, Pannek HW, Speckmann EJ, Zilles K: Heat-shock protein-27 is upregulated in the temporal cortex of patients with epilepsy. Epilepsia 2004;45:1549–1559.
42.
Xi ZQ, Sun JJ, Wang XF, Li MW, Liu XZ, Wang LY, Zhu X, Xiao F, Li JM, Gong Y, Guan LF: HSPBAP1 is found extensively in the anterior temporal neocortex of patients with intractable epilepsy. Synapse 2007;61:741–747.
43.
Sarnat HB, Flores-Sarnat L: α,β-crystallin as a tissue marker of epileptic foci in paediatric resections. Can J Neurol Sci 2009;36:566–574.
44.
Di Domenico F, Sultana R, Tiu GF, Scheff NN, Perluigi M, Cini C, Butterfield DA: Protein levels of heat-shock proteins 27, 32, 60, 70, 90 and thioredoxin-1 in amnestic mild cognitive impairment: an investigation on the role of cellular stress response in the progression of Alzheimer disease. Brain Res 2010;1333:72–81.
45.
Ecroyd H, Carver JA: The effect of small molecules in modulating the chaperone activity of α,β-crystallin against ordered and disordered protein aggregation. FEBS J 2008;275:935–947.
46.
Khandelwal PJ, Dumanis SB, Feng LR, Maguire-Zeiss K, Rebeck G, Lashuel HA, Moussa CE: Parkinson-related parkin reduces α-synuclein phosphorylation in a gene transfer model. Mol Neurodegener 2010;5:47.
47.
Grünewald A, Voges L, Rakovic A, Kasten M, Vandebona H, Hemmelmann C, Lohmann K, Orolicki S, Ramirez A, Schapira AH, Pramstaller PP, Sue CM, Klein C: Mutant parkin impairs mitochondrial function and morphology in human fibroblasts. PLoS One 2010;5:e12962.
48.
Braak H, Del Tredici K, Sandmann-Kiel D, Rüb U, Schultz C: Nerve cells expressing heat-shock proteins in Parkinson’s disease. Acta Neuropathol 2001;102:449–454.
49.
Karch CM, Borchelt DR: An examination of α,β-crystallin as a modifier of SOD-1 aggregate pathology and toxicity in models of familial amyotrophic lateral sclerosis. J Neurochem 2010;113:1092–1100.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.